ArticleJournal of molecular histology2026
Obtusifolin ameliorates pancreatic tissue injury and inflammation by modulating the NFκB signaling.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is a rapid-onset inflammatory disorder of the pancreas, characterized by premature activation of pancreatic digestive enzymes and the development of systemic inflammatory responses. Severe AP is associated with a mortality rate of 10-40%, highlighting the urgent need for effective and targeted therapeutic interventions. Obtusifolin (OBT), a natural compound from Senna obtusifolia, exhibits anti-inflammatory and wound-healing properties. The current study aimed to investigate the effect of OBT against inflammation and tissue injury associated with AP. In vitro, lipopolysaccharide (LPS) and TGF-β-induced differentiation models were employed to investigate the anti-inflammatory and anti-fibrotic effects of OBT in pancreatic stellate cells (PSCs) and PANC-1 cells. In vivo, a cerulein-induced acute pancreatitis mouse model was employed to evaluate the therapeutic potential of OBT through histopathological analysis, ELISA, immunohistochemistry, and western blotting. In vitro results revealed that OBT treatment significantly suppressed the LPS/TGF-β-induced pro-inflammatory and ECM marker expression in PSCs and PANC-1 cells, respectively. In mice, cerulein induction notably increased the pancreatic edema, acinar necrosis, inflammatory infiltration, hemorrhage in tissues of cerulein control, on the other hand, treatment with OBT significantly attenuated the same. Further, OBT treatment significantly reduced the cerulein-induced elevation of inflammatory marker expression (Tnfa, Ccl2, Cxcl10, and Il6), serum α-amylase, β-amylase, and IL-1β levels in a dose-dependent manner. Furthermore, immunohistochemistry and western blot analysis confirmed that OBT ameliorates pancreatitis by modulating the NFκB signaling. These results indicate that obtusifolin attenuates acute pancreatitis by inhibiting inflammatory responses and preserving pancreatic tissue integrity, supporting its potential as a therapeutic candidate for managing acute pancreatitis.
Indexed as
Identifiers
41491435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.